← Back to guidelines
Cardiology67 papers

Infantile nephropathic cystinosis

Last edited: 4/14/2026

Overview

Nephropathic cystinosis is a rare, inherited autosomal recessive disorder characterized by the accumulation of cystine in lysosomes, leading to multi-system involvement including renal failure, endocrine dysfunction, and neurological complications 24.

Diagnosis

  • Early diagnosis through family history and genetic testing 2.
  • Monitoring of white blood cell (WBC) cystine levels to assess cysteamine efficacy 2.
  • Histopathological and immunohistochemical studies for extra-renal manifestations, such as corneal and conjunctival changes 3.
  • Neurological evaluation and imaging (e.g., cerebral atrophy on CT) for central nervous system involvement 4.
  • Management

  • First-line treatment: Cysteamine therapy to reduce cystine accumulation; dosage and monitoring by WBC cystine levels 2.
  • Adjunctive treatments:
  • - Growth hormone for growth retardation 2. - Renal transplantation for end-stage renal failure 2. - Hormone replacement therapy for endocrine deficiencies (e.g., thyroid, adrenal, gonadal) 24. - Management of complications such as portal hypertension and splenomegaly 2.

    Special Populations

  • Pediatrics: Early initiation of cysteamine therapy and regular monitoring of WBC cystine levels crucial 2.
  • Adults: Surveillance for multi-organ dysfunction including neurological, endocrine, and cardiovascular systems 4.
  • Key Recommendations

  • Regular monitoring of WBC cystine levels to ensure effective cysteamine therapy (Evidence: Strong 2).
  • Initiate cysteamine therapy early in life and consider growth hormone for growth retardation (Evidence: Strong 2).
  • Screen for and manage extra-renal manifestations, including endocrine deficiencies and neurological symptoms, in patients with nephropathic cystinosis (Evidence: Moderate 24).
  • Be vigilant for fibrosing colonopathy as a potential adverse effect of cysteamine delayed-release capsules, especially monitoring for non-specific symptoms (Evidence: Weak 1).
  • References

    1 Kishk OA, Kim I, Cheng C, Summan M, Muñoz MA. Fibrosing colonopathy associated with cysteamine bitartrate delayed-release capsules in cystinosis patients. Pediatric nephrology (Berlin, Germany) 2024. link 2 Besouw MT, Van Dyck M, Cassiman D, Claes KJ, Levtchenko EN. Management dilemmas in pediatric nephrology: Cystinosis. Pediatric nephrology (Berlin, Germany) 2015. link 3 Kaiser-Kupfer MI, Chan CC, Rodrigues M, Datiles MB, Gahl WA. Nephropathic cystinosis: immunohistochemical and histopathologic studies of cornea, conjunctiva and iris. Current eye research 1987. link 4 Jonas AJ, Conley SB, Marshall R, Johnson RA, Marks M, Rosenberg H. Nephropathic cystinosis with central nervous system involvement. The American journal of medicine 1987. link90661-9)

    Original source

    1. [1]
      Fibrosing colonopathy associated with cysteamine bitartrate delayed-release capsules in cystinosis patients.Kishk OA, Kim I, Cheng C, Summan M, Muñoz MA Pediatric nephrology (Berlin, Germany) (2024)
    2. [2]
      Management dilemmas in pediatric nephrology: Cystinosis.Besouw MT, Van Dyck M, Cassiman D, Claes KJ, Levtchenko EN Pediatric nephrology (Berlin, Germany) (2015)
    3. [3]
      Nephropathic cystinosis: immunohistochemical and histopathologic studies of cornea, conjunctiva and iris.Kaiser-Kupfer MI, Chan CC, Rodrigues M, Datiles MB, Gahl WA Current eye research (1987)
    4. [4]
      Nephropathic cystinosis with central nervous system involvement.Jonas AJ, Conley SB, Marshall R, Johnson RA, Marks M, Rosenberg H The American journal of medicine (1987)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG